Research Article Details

Article ID: A25409
PMID: 21883436
Source: Diabet Med
Title: Increased prevalence of chronic kidney disease in patients with Type 1 diabetes and non-alcoholic fatty liver.
Abstract: AIMS: We determined whether non-alcoholic fatty liver is associated with an increased prevalence of chronic kidney disease in Type&#8195;1 diabetes. METHODS: We studied 343 patients with Type&#8195;1 diabetes, who had no history of excessive alcohol consumption or other secondary causes of chronic liver disease. Non-alcoholic fatty liver was diagnosed by ultrasonography. Chronic kidney disease was defined as presence of either abnormal albuminuria (i.e., urinary albumin/creatinine ratio &#8805;&#8195;30&#8195;mg/g) or estimated glomerular filtration rate of less than 60&#8195;ml&#8195;min(-1) &#8195;1.73&#8195;m(-2) . RESULTS: Compared with those without steatosis, patients with non-alcoholic fatty liver (n&#8195;=&#8195;182) had significantly lower estimated GFR (83.0&#8195;&#177;&#8195;27 vs. 93.3&#8195;&#177;&#8195;29&#8195;ml&#8195;min(-1) &#8195;1.73&#8195;m(-2) , P&#8195;<&#8195;0.001) and a greater prevalence of abnormal albuminuria (50.0 vs. 20.5%, P&#8195;<&#8195;0.0001) and chronic kidney disease (54.4 vs. 24.2%, P&#8195;<&#8195;0.0001). Multivariable logistic regression analysis revealed that non-alcoholic fatty liver was associated with an increased risk of either abnormal albuminuria (adjusted odds ratio 2.21, 95%&#8195;CI 1.2-4.1, P&#8195;=&#8195;0.01) or chronic kidney disease (adjusted odds ratio 1.93, 95%&#8195;CI 1.1-3.6, P&#8195;=&#8195;0.02), independently of age, gender, smoking status, physical activity, diabetes duration, HbA(1c) , BMI, systolic blood pressure, plasma lipids and use of anti-hypertensive and lipid-lowering medications. CONCLUSIONS: Our findings demonstrate that ultrasound-diagnosed non-alcoholic fatty liver is associated with a higher prevalence of chronic kidney disease in patients with Type&#8195;1 diabetes, independently of several risk factors, including the components of the metabolic syndrome.
DOI: 10.1111/j.1464-5491.2011.03427.x